254454-54-1

Basic information

• Product Name: 1-Boc-3-iodoazetidine
• Synonyms: 1-BOC-3-IODO-AZETIDINE 98%;tert-butyl 3-iodoazetidine-1-carboxylate;tert-Butyl 3-iodoazetidine-1-carboxylate, 1-(tert-Butoxycarbonyl)-3-iodoazetidine;1-N-Boc-3-iodoazetidine;1-Boc-3-iodo-azetidine;N-Boc-3-iodoazetidine;3-Iodoazetidine, N-BOC protected;1-tert-Butoxycarbonyl-3-iodoazetidine
• CAS NO: 254454-54-1
• Molecular Formula: C₈H₁₄INO₂
• Molecular Weight: 283.10673
• EINECS: 1308068-626-2
• Product Categories: Azetidine
• Mol File: 254454-54-1.mol

Chemical Properties

• Boiling Point: 282.037 °C at 760 mmHg
• Flash Point: 124.372 °C
• Appearance: /
• Density: 1.632 g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.5090 to 1.5130
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -3.39±0.40(Predicted)
• Sensitive: Light Sensitive
• CAS DataBase Reference: 1-Boc-3-iodoazetidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-3-iodoazetidine(254454-54-1)
• EPA Substance Registry System: 1-Boc-3-iodoazetidine(254454-54-1)

Safety Data

• Hazard Codes: Xi,N,T
• Statements: 25-36-50
• Safety Statements: 26-45
• RIDADR: UN 3082 9 / PGIII
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 254454-54-1(Hazardous Substances Data)

Usage

Chemical Properties

Colorless to red-brown liquid

Uses

1-Boc-3-iodoazetidine is used as an organic chemical synthesis intermediate.

InChI:InChI=1/C8H14INO2/c1-8(2,3)12-7(11)10-4-6(9)5-10/h6H,4-5H2,1-3H3

Upstream product

• 141699-58-3 3-methanesulfonyloxy-azetidine-1-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 141699-55-0 tert-butyl 3-hydroxyazetidine-1-carboxylate 
• 916899-83-7 tert-butyl 3-{[(trifluoromethyl)sulfonyl]oxy}azetidine-1-carboxylate 
• 142253-55-2 1-(t-butyloxycarbonyl)-azetidine-3-carboxylic acid 
• 19540-05-7 1-azabicyclo<1.1.0>butane 
• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 

Downstream Products

• 206446-39-1 1-tert-butyl 3-(pyridine-2-yl)azetidine-1-carboxylate 
• 206446-44-8 tert-butyl 3-benzoylazetidine-1-carboxylate 
• 206446-46-0 tert-butyl 3-allylazetidine-1-carboxylate 
• 147621-21-4 tert-butyl azetidine-1-carboxylate 
• 1044507-64-3 tert-butyl-3-(4-fluorophenyl)azetidine-1-carboxylate 
• 1044507-62-1 tert-butyl 3-(4'-methylphenyl)azetidine-1-carboxylate 
• 1044507-63-2 tert-butyl 3-(4-acetylphenyl) azetidine-1-carboxylate 
• 1146089-80-6 tert-butyl 3-((6-bromopyridin-3-yl)oxy)azetidin-1-carboxylate 
• 1180654-03-8 tert-butyl 3-(3-cyano-4-(2,4-dichlorophenylamino)-6,7-dimethoxyquinolin-2-yl)-azetidine-1-carboxylate 
• 870526-70-8 tert-butyl 3-(2-trityl-2H-indazol-4-yl)azetidine-1-carboxylate 
• 1227068-60-1 tert-butyl 3-(3-chloropyrazin-2-yl)azetidine-1-carboxylate 
• 1236861-42-9 tert-butyl 3-(4-methylpyridin-2-yl)azetidine-1-carboxylate 
• 1236861-59-8 tert-butyl 3-pyrimidin-2-ylazetidine-1-carboxylate 
• 916900-30-6 tert-butyl 3-[3-(benzyloxy)phenyl]azetidine-1-carboxylate 

Relevant articles and documents

Visible-Light-Mediated C-I Difluoroallylation with an α-Aminoalkyl Radical as a Mediator

Herein, we report a protocol for direct visible-light-mediated C-I difluoroallylation reactions of α-trifluoromethyl arylalkenes with alkyl iodides at room temperature with an α-aminoalkyl radical as a mediator. The protocol permits efficient functionalization of various α-trifluoromethyl arylalkenes with cyclic and acyclic primary, secondary, and tertiary alkyl iodides and is scalable to the gram level. This mild protocol uses an inexpensive mediator and is suitable for late-stage functionalization of complex natural products and drugs.

Copper-Catalyzed Cross-Coupling between Alkyl (Pseudo)halides and Bicyclopentyl Grignard Reagents

The development of a copper-catalyzed cross-coupling between primary and secondary (pseudo)halides and bicyclopentyl Grignard reagents is reported. Highly strained bicyclopentanes can be cross-coupled with a large panel of primary alkyl mesylates and secondary alkyl iodides. The catalytic system is simple and cheap, and the reaction is general and chemoselective.

A 3 - nitro-azetidine -1 - formic acid tert-butyl synthetic method

The invention relates to a 3 - nitro-azetidine - 1 - carboxylic acid tert-butyl synthetic method, mainly solves the industrial synthesis method not suitable for the technical problem. The invention is divided into three steps, 1st step, first of all by compound 1 in the solvent non-water reaction adding sodium borohydride in methanol to obtain compound 2, 2nd step, compound 2 with imidazole, triphenylphosphine and iodine in toluene in reaction to obtain compound 3, 3rd step, compound 3 with urea, sodium nitrite and phloroglucinol in N, N - dimethyl formamide in reaction to obtain the final compound 4, reaction as follows: .

Introduction of Cyclopropyl and Cyclobutyl Ring on Alkyl Iodides through Cobalt-Catalyzed Cross-Coupling

A cobalt-catalyzed cross-coupling between alkyl iodides and cyclopropyl, cyclobutyl, and alkenyl Grignard reagents is disclosed. The reaction allows the introduction of strained rings on a large panel of primary and secondary alkyl iodides. The catalytic system is simple and nonexpensive, and the reaction is general, chemoselective, and diastereoconvergent. The alkene resulting from the cross-coupling can be transformed to substituted cyclopropanes using a Simmons-Smith reaction. The formation of radical intermediates during the coupling is hypothesized.

Regioselective α-benzylation of 3-iodoazetidine via Suzuki cross-coupling

An efficient protocol for the synthesis of α-benzyl azetidines starting from benzylboronic acid pinacol ester derivatives and 3-iodoazetidine was developed. A wide range of α-benzyl azetidine derivatives were obtained in moderate to good yields with high regioselectivity (>99%).

An improved, gram-scale synthesis of protected 3-haloazetidines: Rapid diversified synthesis of azetidine-3-carboxylic acids

Azetidines are increasingly important heterocycles found in a variety of natural products and pharmaceutical compounds. Protected 3-haloazetidines, widely used and versatile building blocks in medicinal chemistry, have been prepared in a one-pot, gram-scale strain-release reaction of 1-azabicyclo[1.1.0]butane from commercially available starting materials. These intermediates were subsequently used to prepare a series of high value azetidine-3-carboxylic acid derivatives including the first reported synthesis of 1-(tert-butoxy-carbonyl)-3-((trifluoromethyl)thio)azetidine-3-carboxylic acid. (Figure pressented)

6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST

The present invention relates to a novel pyrrolidine compound having melanocortin receptor agonist activity or a pharmaceutically acceptable salt thereof, and to pharmaceutical applications thereof. The present invention relates to a pyrrolidine derivative represented by formula [I], wherein ring A represents an optionally substituted aryl group or the like; R1 represents an optionally substituted alkyl group or the like; R2 represents a halogen atom or the like; and R3 is an alkyl group substituted with an optionally substituted aryl group or the like, and R4 is a hydrogen atom or the like; or R3 and R4 are terminally attached to each other, and together with the nitrogen atom to which they are attached, form an optionally substituted nitrogen-containing aliphatic heterocyclic ring that may partially contain a double bond; or to a pharmaceutically acceptable salt thereof.

POLYCYCLIC ANAPLASTIC LYMPHOMA KINASE INHIBITOR

Provided is a polycyclic inhibitor of anaplastic lymphoma kinase as represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, and ring A are as defined in the description. The invention also relates to a method for preparing the compound, a pharmaceutical preparation and a pharmaceutical composition comprising the compound, and use of the compound, the pharmaceutically acceptable salt or stereoisomer thereof in manufacture of a medicament for the treatment and/or prevention of an anaplastic lymphoma kinase-mediated cancer or non-cancer related diseases.

HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY

Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X, X, and Xare N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I foranddiagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.